Recent advances in TNBC reported that PIK3CA mutations have a high prevalence in this subtype of BC [47]. Alpelisib is an FDA approved selective PI3K inhibitor which has demonstrated efficacy in treated PIK3CA-mutated HR+/HER- disease BC according to SOLAR-1’ phase III randomized trial results and might be another treatment option for advanced stages [43,48]. The gene discussed is PIK3CA; the disease is breast cancer.